Tuesday, 11 August 2020


Shenzhen Neptunus invests in drug innovation

04 June 2013 | Analysis | By BioSpectrum Bureau

BioSpectrum Asia Top 20 Survey Rank 17 - Shenzhen Neptunus Bioengineering, China

BioSpectrum Asia Top 20 Survey Rank 17 - Shenzhen Neptunus Bioengineering, China

17a-biospectrum-asia-top-20-survey-rank-17-shenzhen-neptunus-bioengineering-china-profile

Shenzhen Neptunus Bioengineering is a well-recognized name in manufacturing and distribution of pharmaceutical products in China. The company is known for manufacturing approximately 400 different types of products, including chemical pharmaceuticals, biological pharmaceuticals, traditional Chinese medicines, and healthcare products.

These products are used to treat diseases such as respiratory, endocrine and metabolism, tumors, infections, cardiovascular and cerebrovascular, digestive system, and urinary system.

Leveraging on China's reforming landscape, the company managed to achieve 15 percent growth in its annual turnover in 2012 and looks forward to take the revenue higher in the coming year. Shenzhen Neptunus Bioengineering is reforming and reworking its business strategies to work in line with the changing policies of China's healthcare industry and looks forward to meet international standard of pharmaceutical products. Nepstar Chain Drugstore, a part of Neptunus Group is the first drugstore chain in China with 3,000 directly managed stores. The growth of the company is a result of the presence of a large number of talented employees at all levels and management positions.

Shenzhen Neptunus Bioengineering is on the spree of promoting technical innovation for medical and bioengineering industry. It has strong R&D system, manufacturing system, marketing network, logistics channels and rich social resources and the company is investing in technological advancements so as to enhance production and efficiency. Shenzhen Neptunus has set up a highly efficient operation mechanism and scientific R&D system, involving preclinical research and development, analysis test, pilot production, clinical research and new drug registration.

Over the years, the company has achieved production of 100 new products involved in the four fields of chemical medicine, traditional Chinese medicine, bioengineering and health protection food, creating economic and social benefits. The company has been successfully recognized as national hi-tech research firm. The company is undertaking projects including innovative medicine with independent intellectual property, new pharmaceutical preparation and generic drugs in line with the national standard for industrialization of scientific research.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls